Stifel Financial Corp Boosts Position in Edwards Lifesciences Co. (NYSE:EW)

Stifel Financial Corp lifted its holdings in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 11.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 232,738 shares of the medical research company's stock after buying an additional 24,731 shares during the quarter. Stifel Financial Corp's holdings in Edwards Lifesciences were worth $15,358,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Stableford Capital II LLC increased its position in shares of Edwards Lifesciences by 2.7% during the second quarter. Stableford Capital II LLC now owns 6,104 shares of the medical research company's stock valued at $533,000 after acquiring an additional 159 shares in the last quarter. Purus Wealth Management LLC raised its stake in shares of Edwards Lifesciences by 5.2% in the second quarter. Purus Wealth Management LLC now owns 3,212 shares of the medical research company's stock worth $297,000 after purchasing an additional 160 shares during the last quarter. Busey Bank lifted its holdings in shares of Edwards Lifesciences by 1.9% during the second quarter. Busey Bank now owns 8,838 shares of the medical research company's stock valued at $816,000 after purchasing an additional 165 shares in the last quarter. Commerzbank Aktiengesellschaft FI boosted its position in shares of Edwards Lifesciences by 7.4% during the second quarter. Commerzbank Aktiengesellschaft FI now owns 2,415 shares of the medical research company's stock valued at $224,000 after buying an additional 166 shares during the last quarter. Finally, JFS Wealth Advisors LLC increased its holdings in Edwards Lifesciences by 31.1% in the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company's stock worth $46,000 after buying an additional 166 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Price Performance

Shares of EW traded up $0.61 during mid-day trading on Wednesday, reaching $74.00. The company had a trading volume of 2,273,191 shares, compared to its average volume of 4,646,462. The company has a market capitalization of $43.65 billion, a P/E ratio of 10.60, a P/E/G ratio of 3.52 and a beta of 1.12. The company's 50-day moving average is $68.92 and its 200-day moving average is $74.19. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.67. The firm had revenue of $1.35 billion for the quarter, compared to analysts' expectations of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The business's revenue for the quarter was up 8.9% on a year-over-year basis. During the same period last year, the firm earned $0.59 earnings per share. On average, equities analysts anticipate that Edwards Lifesciences Co. will post 2.56 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have recently commented on EW shares. Robert W. Baird reduced their price target on shares of Edwards Lifesciences from $73.00 to $68.00 and set a "neutral" rating for the company in a research note on Friday, October 25th. UBS Group decreased their price objective on Edwards Lifesciences from $90.00 to $75.00 and set a "neutral" rating on the stock in a research report on Tuesday, September 10th. Morgan Stanley reissued an "equal weight" rating and set a $70.00 price target on shares of Edwards Lifesciences in a research note on Friday, October 11th. Barclays lifted their target price on Edwards Lifesciences from $85.00 to $88.00 and gave the company an "overweight" rating in a research report on Monday, December 2nd. Finally, Evercore ISI reduced their price target on Edwards Lifesciences from $76.00 to $70.00 and set an "in-line" rating on the stock in a research report on Tuesday, October 1st. Seventeen equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $78.65.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $69.51, for a total value of $347,550.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,262,521.36. This trade represents a 9.63 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Larry L. Wood sold 25,000 shares of the stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the sale, the insider now directly owns 198,526 shares of the company's stock, valued at approximately $13,084,848.66. The trade was a 11.18 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 35,000 shares of company stock worth $2,323,150 in the last 90 days. Corporate insiders own 1.27% of the company's stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.